Asymmetric Bow-Tie Dendrimers as Versatile Platform for Drug Delivery and Diagnosis

Background:

Dendrimers are nano-sized globular macromolecules that have been well studied as a drug delivery vehicles. Their convenient synthesis strategy, easy functionalization of the terminal end group and versatility in designing, make dendrimers such as PAMAM, a choice for drug carrier. Additionally dendrimers as macromolecular carrier have large loading capacity to achieve high concentration at tumor sites. Therefore a controlled strategy to functionalize dendrimers with multiple molecules such as targeting module, cytotoxic drug and/ or fluorescent moiety coupled with their purification strategy that achieves batch to batch consistency is critical for fully exploiting the field of dendrimer based tumor targeting.

Technology Overview:

To overcome the inconsistency associated with multi-functionalization of dendrimers, Researchers at Stony Brook University developed an asymmetric bow-tie dendrimer construction strategy. Using this strategy researchers developed and tested the efficacy of a novel bow-tie dendrimer, bearing a PEGylated spacer that improve solubility, vitamin as a tumor targeting module and a new generation toxoid. In summary, this technology introduces novel multifunctional asymmetric bow-tie dendrimers as a robust platform for drug delivery systems and diagnostic agents. Development Stage: _In vitro_ data is available.

Advantages:

- High loading capacity - Increased concentration at target sites - Allows controlled functionalization of dendrimer surface  - Robust chemistry and batch-to-batch consistency

Applications:

- Drug delivery - Therapeutics - Imaging  - Research

Intellectual Property Summary:

Patent application submitted

Stage of Development:

Utility application pending (#14/917,344)

Licensing Status:

The univeristy seek to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Potential:

Development partner,Commercial partner,Licensing

Additional Information: